RESUMEN
The aim of the present study was to investigate whether the genetic polymorphism of CYP2C19 plays a role in susceptibility to bronchial asthma. 104 healthy individuals who visited our hospital, including hospital staff, and 97 patients with bronchial asthma [62 atopic and 35 nonatopic] participated in this study. CYPC19[*]2 and CYP21C9[*]3 alleles were detected by using LightCycler and CYP2C19 mutation detection kits by real-time PCR with LightCycler. The CYP2C19[*]3 genotype was found to be the wild type in all cases, and in the control group, the CYP2C19[*]2 heterozygous genotype had a 2.46-fold increased risk of bronchial asthmacompared with the CYPC19[*]2 homozygous wild genotype in the control group[p = 0.01, OR = 2.46, 95% CI 1.24-4.88]. Our data suggest that the CYP2C19*2 heterozygous genotype may be involved in the development of bronchial asthma